MNMD vs CMPS vs ATAI vs CYBN vs MGRX

For growth investors, Atai Beckley N.

V (ATAI) is the stronger pick with -1. 9% revenue growth year-over-year, versus -15. 8% for Mangoceuticals, Inc. (MGRX). Analysts rate Mind Medicine (MindMed) Inc. (MNMD) a "Buy" — based on 1 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Mind Medicine (MindMed) Inc.

(MNMD) delivered a total return of -58. 8%, compared to -99. 5% for Mangoceuticals, Inc. (MGRX). Over 10 years, the gap is even starker: MNMD returned +512. 1% versus CYBN's -99. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Mangoceuticals, Inc.

(MGRX) is the lower-risk stock at 0. 90β versus Mind Medicine (MindMed) Inc. 's 1. 68β — meaning MNMD is approximately 86% more volatile than MGRX relative to the S&P 500. On balance sheet safety, Mangoceuticals, Inc. (MGRX) carries a lower debt/equity ratio of 2% versus 21% for Atai Beckley N. V — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Atai Beckley N.

V (ATAI) is pulling ahead at -1. 9% versus -15. 8% for Mangoceuticals, Inc. (MGRX). On earnings-per-share growth, the picture is similar: Cybin Inc. grew EPS 93. 5% year-over-year, compared to -1273. 3% for Mind Medicine (MindMed) Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Mind Medicine (MindMed) Inc.

(MNMD) is the more profitable company, earning 0. 0% net margin versus -484. 6% for Atai Beckley N. V — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MNMD leads at 0. 0% versus -333. 4% for ATAI. At the gross margin level — before operating expenses — ATAI leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

In this comparison, MGRX (100.

0% yield) pays a dividend. MNMD, CMPS, ATAI, CYBN do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Mangoceuticals, Inc.

(MGRX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 90), 100. 0% yield). Cybin Inc. (CYBN) carries a higher beta of 1. 52 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MGRX: -99. 5%, CYBN: -99. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: MNMD is a small-cap quality compounder stock; CMPS is a small-cap quality compounder stock; ATAI is a small-cap quality compounder stock; CYBN is a small-cap quality compounder stock; MGRX is a small-cap income-oriented stock. MGRX pays a dividend while MNMD, CMPS, ATAI, CYBN do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.